Merck shares climb after drug trial ends early – Businessweek

Merck shares climb after drug trial ends early
Businessweek
The potential drug is crucial for Merck, the world's third largest drugmaker, which will lose U.S. patent protection for its top seller, the asthma and allergy drug Singulair, next month. Singulair brought in $5.5 billion in sales last year, but a loss

and more »

View full post on world asthma day – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *